Smartlab Europe

IT & Data Management

Astrazeneca, Mutabor Are Now Recognised As Allies By OPTIMA

The European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA) have collaborated on the Innovative Medicines Initiative (IMI), which has announced the commencement of the public-private research programme OPTIMA which is defined as Optimal Treatment for...

NPA And Charac Collaborating To Accelerate Digitalization

The National Pharmacy Association (NPA) and Charac, an NHS-integrated one-stop gateway for independent community pharmacists, have established a long-term cooperation to enable pharmacies to provide the wide variety of services required to support the general public. It comes after Therese...

EU Data Transmission On The Accessibility of Human Tissue

The Committee of Ministers for the Council of Europe has recommended that Member States compile information on the usage and supply of tissues and cells so that final users can receive them right away. The Council emphasized in a...

Maintain a Greater IDMP Strategy in a Changing Regulatory Landscape

After more than 10 years of preparation, the new Identification of Medicinal Products (IDMP) standard is set to go live in 2023. IDMP facilitates the unique identification of medicinal products in an effort to promote global harmonization of data,...

FDA Experts Favor ALS Drug Amylyx, Shifting Former Stance

A group of Food and Drug Administration advisers has recently come out in favour of a carefully monitored ALS drug, increasing the likelihood that the agency will approve it in the coming weeks. The expert group voted 7-2 in favour...

Big Data Steering Group To Optimize Data Quality, Visibility

A third workplan with measures due by 2025 has been released by the joint Big Data Steering Group of the European Medicines Agency (EMA) as well as the Heads of Medicines Agencies (HMA). The new strategy, according to EMA, will...

Cyclerion Provides Information On Schizophrenia Treatment

Positive top-line statistics from Cyclerion Therapeutics' clinical investigation of CY6463 for the treatment of cognitive impairment associated with schizophrenia have been released. It concerns people with stable schizophrenia who are taking a stable dose of a single atypical antipsychotic...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »